The Fund for Innovative Biopharmaceuticals of ZHONGKIN Capital completed the fund raising

the key stage in the fight against the new coronavirus pneumonia, there is encouraging news in the equity investment circle. The Zhongjin Qide (Xiamen) Innovative Biopharmaceutical Equity Investment Fund ("Zhongjin Qide"), managed by COFKIN Capital Operations Co., Ltd. ("ZHONGKIN Capital"), completed the filing, with an initial size of more than RMB1.6 billion.The establishment of the fund is the first equity investment fund focused on innovative medicine initiated by the private equity fund manager of a securities company in China, and its establishment marks a major breakthrough in the layout of CAPITAL in the biopharmaceutical industry. With excellent performance brand reputation and investment management capabilities, ZHONGC Kaide has won the recognition and support of a number of well-known parent funds, institutional investors, listed companies and COC Wealth clients, with a relatively short period of time to complete the over-raising, becoming the largest RMB biopharmaceutical fund in the past two years.After the outbreak, ZHONGC Qide first began to closely communicate and collaborate with a number of innovative pharmaceutical companies to invest in, helping enterprises to accelerate the development and production of nucleic acid testing reagents, therapeutic antibodies, antiviral drugs and vaccines for new coronavirus pneumonia. The related work has been highly recognized and supported by the China Securities Investment Fund Industry Association, so ZHONGKIN Qide became the first private equity investment fund to complete the filing through the "Green Channel for the filing of management products in the field of epidemic prevention and control".Under the epidemic, China's biopharmaceutical industry not only accepted great challenges, but also ushered in the opportunity for development, ZHONGKIN Kaide will continue to pay attention to the world's leading level of biomedical and biotechnology enterprises, fully grasp china's pharmaceutical reform policy dividends, pharmaceutical industry upgrade dividends, pharmaceutical enterprises listed dividends and other investment opportunities, systematically play the depth of research in the pharmaceutical industry, high-quality project coverage and capital market exit strength of China's national health. (Arterial mesh)